House Over­sight Com­mit­tee sub­poe­nas Ab­b­Vie over 'woe­ful­ly in­ad­e­quate' doc­u­ment pro­duc­tion in price-goug­ing probe

Con­gress is turn­ing up the heat on Ab­b­Vie $AB­BV over its pric­ing poli­cies.

The House Com­mit­tee on Over­sight and Re­form is plan­ning to sub­poe­na the bio­phar­ma as part of a 2019 probe in­to the al­leged price-goug­ing of Hu­mi­ra and Im­bru­vi­ca, ac­cord­ing to a memo re­leased Mon­day. The move comes af­ter the late Eli­jah Cum­mings, who chaired the com­mit­tee, opened the in­ves­ti­ga­tion in­to a dozen drug­mak­ers over 18 months ago and Ab­b­Vie did not pro­vide law­mak­ers with re­quest­ed doc­u­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER